Latest News from FibrosIX

FibrosIX Inc. Awarded Competitive Grant from the National Science Foundation

FibrosIX Team2021-04-02T14:51:27-04:00March 1, 2021|

Small Business Innovation Research Program Provides Seed Funding for R&D East Lansing, Michigan, March 1, 2021 – FribrosIX has been awarded a National Science [...]

FibrosIX Inc. SBIR grant from the National Science Foundation

FibrosIX Team2021-02-22T10:00:40-05:00February 22, 2021|

FibrosIX Inc. has been awarded a National Science Foundation (NSF) SBIR grant to explore the ability of our compounds to quiet hyper-inflammation (2035857 QUIETING [...]

Starting the New Year off right

FibrosIX Team2021-01-28T09:01:44-05:00January 28, 2021|

From the team at FibrosIX Inc, we would like to wish everyone a happy and safe start to 2021! After a tumultuous 2020, FibrosIX [...]

FibrosIX will be participating in Digital RESI Investor Conference (Sept 14-16)

FibrosIX Team2020-09-15T13:50:24-04:00September 15, 2020|

We are pleased to announce that FibrosIX will be participating in the September 2020 Digital RESI Investor Conference, taking place from September 14 - [...]

FibrosIX Technology Featured by Michigan Drug Discovery and University of Michigan Tech Transfer

FibrosIX Team2020-09-15T13:49:32-04:00July 6, 2020|

Michigan Drug Discovery and the University of Michigan Tech Transfer Office highlighted the FibrosIX Inc. antifibrotic technology on their website. Michigan Drug Discovery is [...]

FibrosIX Selected for 2020 NCI SBIR Investor Initiatives

FibrosIX Team2020-09-15T13:46:21-04:00June 22, 2020|

FibrosIX was selected to participate in the 2020 National Cancer Institute (NCI) SBIR Investor Initiatives. The Investor initiatives program provides specialized training to start-up [...]

US Patent issued for the FibrosIX lead compound CCG-257081

FibrosIX Team2020-09-16T08:44:10-04:00May 26, 2020|

The US Patent # 10,662,183, entitled: “Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the [...]

Dr. Kendell Pawelec joins FibrosIX Inc. as CEO

FibrosIX Team2020-09-15T13:42:10-04:00January 20, 2020|

We are pleased to welcome Dr. Kendell Pawelec to the FibrosIX Inc. team as CEO. She joins the executive team to build the strategic [...]

FibrosIX Inc. SBIR grant from the National Cancer Institute

FibrosIX Team2020-09-15T13:41:02-04:00September 1, 2018|

FibrosIX Inc. has been awarded an SBIR grant from the National Cancer Institute of NIH to advance the development of our compounds in fibrotic [...]